While one avenue of targeting melanoma involved inhibiting the BRAF kinase, drug resistance ensued from BRAF-addicted cancer cells, mediated through downregulation of sex-determining region Y-related high mobility group box 10 protein (SOX10) via miRNA-338, which was associated with Nrp1 expression in melanoma (91). Here, BRAF is linked to melanoma.